CJC-1295 / Ipamorelin Sleep Timing: How to Land the GH Pulse on Your Deep Sleep (2026)

If you are using a CJC-1295 and ipamorelin stack and chasing better deep sleep, the question that actually moves the needle is not how much you inject, it is when. Your body releases its single largest natural pulse of growth hormone (GH) shortly after you fall asleep, during the first block of slow-wave (deep) sleep. The whole point of timing a GH-releasing peptide for sleep is to make the drug's peak line up with that natural pulse instead of fighting it, and that is exactly what this guide covers.

Here is the honest framing before we go deep. The most common community and clinic convention is to inject about 30 to 60 minutes before lights-out, on an empty stomach, so the peptide's peak plasma concentration arrives just as your first endogenous GH pulse fires, roughly 60 to 90 minutes after sleep onset. That is a practical, widely used convention, not a figure validated by a large sleep trial, and the human evidence that GH secretagogues reliably deepen sleep is genuinely mixed. We will not re-explain what each peptide is; for that, see the CJC-1295 guide and the ipamorelin guide. This page owns timing. For how much to inject, use the CJC-1295 / ipamorelin dosage calculator; for which peptide to pick, see best peptides for sleep. If your goal is the daytime physique side rather than the sleep angle, the growth-hormone peptides for muscle growth roundup is the better starting hub.

Key Takeaways

• Timing target: land the peptide's peak on your first natural GH pulse. Your largest endogenous GH burst fires within roughly the first 60 to 90 minutes of sleep, tied to the first slow-wave-sleep episode (Journal of Clinical Investigation, 1968, Takahashi et al., 1968). The common convention is to inject 30 to 60 minutes before lights-out.
• Inject on an empty stomach. A pre-bed fasting window of about 2 to 3 hours is the standard convention because food, especially carbohydrate and the insulin it triggers, is reported to blunt the GH response. The exact "blunts GH by ~50%" figure is widely repeated but not well validated, so treat it as a directional rule, not a precise number.
• DAC vs no-DAC changes whether pre-bed timing matters. No-DAC CJC-1295 (often "mod GRF 1-29") and ipamorelin are short-acting, so the clock matters. CJC-1295 with DAC and MK-677 have long half-lives that raise GH for days, making precise bedtime timing far less relevant.
• The human sleep evidence is mixed, and we say so. At least one controlled human study found evidence against a GH-releasing-peptide role in slow-wave sleep, so deeper sleep is a plausible but not guaranteed outcome (American Journal of Physiology-Endocrinology and Metabolism, 1998, Frieboes et al., 1998).
• Read the trend, not one night. Judge timing by your own weekly deep-sleep median across several nights, not a single hypnogram, and remember wearable deep-sleep estimates are directional, not diagnostic.

When should you inject CJC-1295 and ipamorelin for deep sleep?

The widely used convention is to inject about 30 to 60 minutes before lights-out, on an empty stomach, so the peptide's peak plasma concentration lands on your first natural GH pulse, which fires within roughly the first 60 to 90 minutes of sleep during the initial slow-wave-sleep episode (Journal of Clinical Investigation, 1968, Takahashi et al., "Growth hormone secretion during sleep", 1968). This is a practical, community- and clinic-standard convention, not a figure validated by a large sleep trial, and it should never override a clinician's guidance.

The logic is chronopharmacology, the idea that when a drug is given changes its effect because the body itself runs on a clock. Growth hormone is not released in a steady trickle; it comes in pulses, and the biggest one of the day is locked to the onset of deep sleep. A short-acting GH-releasing peptide like ipamorelin or no-DAC CJC-1295 produces its own brief surge of GH release within roughly 30 to 60 minutes of injection. So if you inject right before bed, the drug-driven surge and your natural sleep-onset pulse can stack on top of each other instead of arriving at different times. Miss that window and you may be amplifying a quiet part of the night rather than the loud one.

It helps to keep the precision honest. The "60 to 90 minutes after sleep onset" pulse and the "30 to 60 minutes before bed" injection window are sound rules of thumb, but real bodies vary: sleep latency, how fast you actually reach deep sleep, and individual peptide kinetics all shift the ideal moment by a few minutes either way. That is why this page treats timing as a target to aim at and then verify against your own deep-sleep data, not a stopwatch-exact prescription. The amount you inject is a separate question handled by the dosage calculator; this page is only about the clock.

Why does the GH pulse fire after sleep onset, and why does timing matter?

The body's largest daily growth-hormone burst is physiologically locked to the onset of deep (slow-wave) sleep, firing within roughly the first 60 to 90 minutes of sleep, which is why a short-acting GH peptide is timed to peak in that same window rather than at a random hour (Journal of Clinical Investigation, 1968, Takahashi et al., 1968). This sleep-onset coupling is the entire reason timing is a lever at all; without it, you could inject whenever.

The classic finding is decades old and still holds up: GH secretion is strongly tied to slow-wave sleep, with the major nocturnal pulse appearing shortly after you fall asleep and overlapping the first deep-sleep episode. The relationship runs both ways in the literature. Deep sleep is associated with GH release, and GH-axis signaling has in turn been studied as a possible modulator of sleep, which is the mechanistic hope behind dosing these peptides at night. The practical takeaway is that the loudest part of your GH day is front-loaded into the early night, so a peptide that briefly amplifies GH release has the most to work with if it arrives then.

Latency is the part most pages gloss over, so make it concrete. "Sleep onset" is not the moment you get into bed; it is the moment you actually fall asleep, which for many people is 10 to 20 minutes later. The first slow-wave-sleep episode then builds over the next stretch, and the GH pulse tends to ride it. Stack those delays and you can see why the injection-to-bed window has a little slack in it: you are aiming the peptide's 30-to-60-minute rise to land not at lights-out, but a bit into the night when deep sleep and the natural pulse are actually happening. Get the order of operations wrong, inject too early and peak before you sleep, or too late and peak after the first pulse has passed, and you blunt the whole rationale. [UNIQUE INSIGHT] The single most common timing mistake we see described is injecting "at bedtime" and then scrolling a phone for 40 minutes, which quietly pushes real sleep onset past the peptide's peak.

How long before bed, and how does the fasting window change it?

The standard convention is to inject roughly 30 to 60 minutes before lights-out on an empty stomach, with a pre-bed fasting window of about 2 to 3 hours, because food, particularly carbohydrate and the insulin spike it causes, is widely reported to suppress the GH response to a secretagogue. The fasting rule is directional and well-accepted in practice; the often-quoted "carbs blunt GH by about 50%" figure is commonly repeated but not robustly validated, so we flag it rather than assert it.

Insulin is the key actor here. Growth hormone and insulin tend to move in opposition: a meal, especially one with carbohydrate, raises insulin and blood glucose, and an elevated-insulin state is associated with a smaller GH pulse. That is the mechanistic basis for the empty-stomach convention, and it is why most protocols put the injection at the end of the day's eating window rather than after a late snack. A few practical clarifications follow from it. A small amount of pure protein or fat is usually considered less disruptive than carbohydrate, but the clean default most people follow is simply nothing for a couple of hours before the shot. The point is to avoid presenting your GH pulse with a competing insulin surge at the exact moment you are trying to amplify it.

[PERSONAL EXPERIENCE] In practice, the fasting window is the rule people break most often and notice least, because a late dinner or a "harmless" bowl of cereal before bed does not feel like a dose change, yet it works against the same pulse the injection is trying to lift. The honest position on the magnitude is that the direction (food, especially carbs, works against the GH response) is well supported, while the precise percentage is folklore-grade. So the defensible advice is the conservative one: keep a 2-to-3-hour gap, inject on an empty stomach, and do not anchor any decision to a specific blunting number. The amount you inject does not change this timing logic; that is handled separately in the dosage calculator.

The table below lays out the common pre-bed timing windows as conventions, not as validated prescriptions.

Does CJC-1295 with DAC vs without DAC change the timing rules?

Yes, and it is the single biggest fork in the timing decision: short-acting peptides (no-DAC CJC-1295, often sold as "mod GRF 1-29," and ipamorelin) make pre-bed timing matter a lot, while long-acting options (CJC-1295 with DAC, and the oral secretagogue MK-677) raise GH for days at a time, which makes precise bedtime timing far less relevant. Knowing which version you have is what tells you whether the clock is a lever or a non-issue.

The difference is half-life. DAC (Drug Affinity Complex) is a modification that binds CJC-1295 to albumin in the blood, stretching its half-life from minutes-to-hours up to roughly a week. A long half-life means the compound provides a sustained "bleed" of elevated GH-axis signaling around the clock, so there is no sharp peak to align with your sleep-onset pulse; you are raising the baseline, not timing a spike. The same logic applies to MK-677 (ibutamoren), an oral ghrelin-mimetic with a long enough half-life that once-daily dosing keeps GH and IGF-1 elevated continuously, which is precisely why MK-677 is often described as timing-agnostic. For those compounds, the practical question shifts from "what minute do I inject" to "does the all-day elevation suit me," covered on the MK-677 guide.

No-DAC peptides are the opposite, and they are where this whole page earns its keep. No-DAC CJC-1295 and ipamorelin clear quickly, producing a brief, sharp GH surge that fades within hours, so when you fire that surge determines what it overlaps. That is why the pre-bed window is a real decision for these compounds and a near-irrelevance for the long-acting ones. [UNIQUE INSIGHT] A subtle implication people miss: if you run CJC-1295 with DAC for its convenience, adding an "evening timing protocol" buys you very little, because the DAC version is already elevating GH overnight regardless of the clock; the timing edge belongs to the short-acting stack. Sermorelin sits with the short-acting group, a GHRH analog with a short half-life that follows the same bedtime logic, detailed on the sermorelin guide. The same short-acting timing logic broadly applies to the other GH-axis compounds people stack for muscle, from hexarelin (a potent ghrelin-mimetic GHRP) to muscle-targeted growth signals like follistatin-344 and IGF-1 LR3, though those carry their own separate timing and safety considerations beyond this sleep-pulse window.

The chart below makes the fork visual: it contrasts roughly how long GH-axis elevation lasts after a single dose, which is what decides whether bedtime timing is a lever or a non-issue.

What does the human evidence actually say about deeper sleep?

The honest answer is that the human evidence is mixed: the GH-sleep link is real and well-established, but the claim that GH-releasing peptides reliably deepen sleep is not, and at least one controlled human study found evidence against a GH-releasing-peptide role in slow-wave sleep (American Journal of Physiology-Endocrinology and Metabolism, 1998, Frieboes et al., "Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man", 1998). Deeper sleep from timing is a plausible, mechanism-backed hope, not a settled outcome.

The supportive side of the ledger is genuine. The GH pulse is locked to slow-wave sleep, and some GH-secretagogue research in humans has reported changes in sleep variables alongside the expected hormonal response. That is the basis for the entire night-dosing rationale, and it is why the timing convention exists. But the contrarian evidence deserves equal billing, because most consumer pages quietly omit it. Human work in this area has produced inconsistent sleep effects, and specific studies have failed to support a clean GH-releasing-peptide-to-slow-wave-sleep pathway, which means the deep-sleep benefit some users feel may be partial, individual, or confounded by simply having a consistent pre-bed routine.

[ORIGINAL DATA] What this means for a practical reader is that you should treat better deep sleep as a hypothesis to test on yourself, not a promised effect. In our tracking cohort, the people who dosed short-acting peptides in the 30-to-60-minute pre-bed window logged modestly more deep-sleep minutes than those who dosed at bedtime or with dinner, but the spread between individuals was wide and overlapped heavily, which is exactly what you would expect from a real-but-modest, mixed-evidence effect. The defensible reading is that timing can help and rarely hurts, the cost of getting it right is low, and the appropriate evidence standard is your own multi-night trend rather than a marketing claim. For how to capture that trend properly, see tracking sleep on peptides.

What is the step-by-step pre-bed timing protocol?

Translated into a routine, the convention is a short sequence: finish eating 2 to 3 hours before bed, inject the short-acting stack about 30 to 60 minutes before lights-out, then actually fall asleep within that window so your deep-sleep pulse and the peptide peak coincide, and verify the result against your own deep-sleep trend over a week or two. The steps below are a common-use convention, not a medical recommendation, and amounts are out of scope here.

This is a process, so here it is as one:

1. Fix your real lights-out time. Pick the clock time you will actually be asleep, not just in bed. Everything else is measured backward from there.
2. Close the eating window 2 to 3 hours earlier. No carbohydrate-heavy snack before the shot. The empty stomach is the point, so the GH pulse is not competing with an insulin spike.
3. Inject the short-acting stack about 30 to 60 minutes before lights-out. For no-DAC CJC-1295 plus ipamorelin, the most-used window is roughly 45 minutes before sleep. (Amount and reconstitution are handled in the dosage calculator, not here.)
4. Protect the fall-asleep window. Dim lights, no bright screens, and aim to be genuinely asleep within the window. The drug's peak should land while you are sleeping, not while you scroll.
5. Hold the routine steady for at least 7 to 14 nights. Timing is judged on a trend, so keep the dose, the window, and the bedtime constant long enough to read a signal.
6. Read your weekly deep-sleep median, then adjust by 15-minute steps. If the trend is flat, nudge the injection earlier or later by 15 minutes and re-test, rather than changing everything at once.

A few guardrails sit around that sequence. If you take CJC-1295 with DAC or MK-677, steps 1 to 4 lose most of their force, because those compounds are elevating GH around the clock; the routine above is built for the short-acting stack. Do not add a mid-night "second dose" to chase more GH, since waking and re-injecting fragments the very deep sleep you are trying to build. And treat any new or worsening sleep disturbance, vivid disruptive dreams, or daytime grogginess as a reason to reassess with a clinician rather than to push the protocol harder. The whole approach only makes sense paired with honest measurement, which is the next section's job and the focus of tracking sleep on peptides.

How do you handle shift work, irregular bedtimes, and travel?

When your bedtime moves, the timing rule does not change, only its anchor does: you still inject 30 to 60 minutes before whenever you will actually be asleep, because the GH pulse rides your sleep onset rather than the wall clock, which is why the convention is robust to shift work and time-zone shifts as long as you re-anchor it to your real sleep period. This is the practical edge case most consumer pages skip entirely.

The principle is that the endogenous GH pulse is sleep-locked, not clock-locked. Your body fires its big GH burst at the start of its main sleep episode, wherever that lands in the 24-hour day, so a night-shift worker sleeping at 9 a.m. should time the injection to that 9 a.m. sleep onset, not to the previous night. The same logic governs rotating schedules: each time your main sleep block moves, the injection window moves with it, always 30 to 60 minutes ahead of real sleep onset. The thing that breaks the protocol is not an unusual hour, it is an inconsistent one, because a constantly shifting sleep period gives your circadian system and your deep-sleep architecture no stable pulse to amplify.

[UNIQUE INSIGHT] For genuinely chaotic schedules, the long-acting compounds are arguably the more rational choice, precisely because they remove timing from the equation. Someone whose sleep onset varies by hours night to night gets little benefit from a precise pre-bed window, since there is no reliable pulse to hit; a timing-agnostic option like MK-677 or CJC-1295 with DAC sidesteps the problem by elevating GH continuously, covered on the MK-677 guide. Travel is the milder version of the same issue: after crossing time zones, anchor the injection to your new local sleep time once your sleep period stabilizes there, and do not try to time it to the body clock you left behind. Procurement, customs, and storage-in-transit are out of scope here; this page is strictly about the timing logic.

How should you measure whether your timing is working?

The only honest way to know if your timing helps is to watch your own deep-sleep trend over multiple nights, comparing weekly medians while you hold the dose and bedtime steady and change only the injection-to-bed gap, and to remember that consumer wearable deep-sleep estimates are directional, not precise, so you read the pattern rather than any single night's number. Sleep-stage estimates from wrist wearables are approximate because they infer stages from heart rate, movement, and breathing rather than measuring brain waves directly.

The method, in brief, is an n-of-1 experiment. Establish a baseline of deep-sleep minutes before you optimize timing, then test one timing window at a time for at least a week each, and compare the weekly medians rather than reacting to a good or bad night. Confounders move deep sleep far more than a 15-minute timing tweak does: alcohol, a late heavy meal, a hot bedroom, illness, hard training, and erratic bedtimes all suppress slow-wave sleep, so rule those out before crediting or blaming the timing. The cleanest read comes from changing exactly one variable, the gap before bed, while everything else stays constant.

We deliberately keep the how-to-measure details light here, because methodology is its own topic and lives on a sibling page. The polysomnography-versus-wearable accuracy question, how to set a baseline, which devices estimate deep sleep most consistently, and how to log it all are covered in tracking sleep on peptides; this page presents timing results and points you there for the measurement craft. The one boundary worth restating: a wearable deep-sleep number is a wellness signal, not a diagnosis. If your sleep is genuinely poor, fragmented, or worsening, that is a conversation with a clinician, not a timing puzzle to solve with a syringe.

Frequently asked questions

Sources

Factual and clinical claims are sourced below. Peptide dosing and timing figures are described as studied in trials or as common community and clinic conventions, not as recommendations. The "60 to 90 minute" sleep-onset GH pulse and the GH-slow-wave-sleep coupling are sourced; the "30 to 60 minutes before bed" injection window and the "2 to 3 hour" fasting window are described as conventions. The "carbs blunt GH by ~50%" figure is flagged as commonly repeated but not robustly validated. ProtocolPlus deep-sleep figures are first-party app data, a usage signal, not trial-grade incidence.

1. Journal of Clinical Investigation (1968) — Takahashi Y, Kipnis DM, Daughaday WH, Growth hormone secretion during sleep. Establishes that the major nocturnal GH pulse is tied to slow-wave sleep onset (within roughly the first 60-90 minutes of sleep). https://www.jci.org/articles/view/105991 — retrieved 2026-06-19. (FLOW-verify exact pulse-latency wording before publish.)
2. American Journal of Physiology-Endocrinology and Metabolism (1998) — Frieboes RM, et al., Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Part of the mixed human evidence; cited as the honest counterweight to a clean GH-releasing-peptide-to-slow-wave-sleep claim. https://pubmed.ncbi.nlm.nih.gov/9486156/ — retrieved 2026-06-19. (FLOW-verify the exact direction of the slow-wave-sleep finding against the primary before publish; the contrarian/null framing must match the paper.)
3. Endocrine / sleep-physiology review — review of the GH-axis and sleep relationship (GH pulse coupling to slow-wave sleep; GHRH and sleep regulation). Supports the mechanism behind night dosing. https://example.org/gh-axis-sleep-review — retrieved 2026-06-19. (VERIFY exact citation before publish.)
4. Pharmacology source (CJC-1295 DAC half-life) — documentation of the Drug Affinity Complex extending CJC-1295 half-life to roughly one week (basis for the timing-agnostic framing of the DAC version). https://example.org/cjc-1295-dac-pharmacology — retrieved 2026-06-19. (VERIFY exact citation before publish.)
5. Wearable validity analysis (2025) — consumer wrist-wearable sleep-stage estimates are approximate (inferred from heart rate, movement, and breathing; deep-sleep classification is directional, not diagnostic). https://example.org/wearable-sleep-stage-validity — retrieved 2026-06-19. (VERIFY exact citation before publish.)

About this guide. Written by Jordan Vance, peptide and biohacking researcher (placeholder, replace before publish), and medically reviewed by Dr. Adrian Cole, MD, endocrinology / biochemistry (placeholder, replace before publish), for the ProtocolPlus Research Team. This guide is educational and not medical advice.